We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Rockwell Medical Inc | NASDAQ:RMTI | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | -2.65% | 1.47 | 1.47 | 1.48 | 1.524 | 1.42 | 1.48 | 120,475 | 17:15:19 |
From Apr 2019 to Apr 2024
By Chris Wack
Rockwell Medical Inc. (RMTI) shares rose 23% to $2.85 after the company said it has entered into license and supply agreements with a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (524715.BY) for the rights to commercialize Triferic ferric pyrophosphate citrate in India.
Rockwell Medical said Sun Pharma will be the exclusive development and commercialization partner for Triferic in India, and Rockwell Medical will supply the product to Sun Pharma.
In consideration for the license, Rockwell Medical said it will receive an upfront fee, and will be eligible for milestone payments and royalties on net sales.
Rockwell Medical said a joint alliance committee, comprised of members from Rockwell Medical and Sun Pharma, will guide the development and execution for Triferic in India. Sun Pharma will be responsible for all clinical, regulatory and commercialization activities.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 15, 2020 12:56 ET (17:56 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Rockwell Medical Chart |
1 Month Rockwell Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
